Michael Gale, Jr

Title: Michael Gale, Jr: Innovator in Viral Research

Introduction

Michael Gale, Jr. is a prominent inventor based in Dallas, TX (US). He has made significant contributions to the field of viral research, particularly in understanding how host cell permissiveness to viral replication can be reduced. His innovative work has implications for treating infections caused by various pathogenic human viruses.

Latest Patents

Michael Gale, Jr. holds a patent titled "Prenylation inhibitors reduce host cell permissiveness to viral replication." This patent describes a method for reducing the permissiveness of human cells to the replication of susceptible pathogenic human viruses by treating the cells with a selective inhibitor of prenylation of a host cell protein. The method involves contacting human cells subject to infection with an effective amount of a selective inhibitor of a prenylation enzyme, confirming a resultant reduction in permissiveness to viral replication. The targeted viruses, particularly from the Flaviviridae family, are characterized by the absence of a CXXX box and a prenylated viral protein, making them reliant on host protein prenylation for replication.

Career Highlights

Michael Gale, Jr. is affiliated with The University of Texas System, where he conducts his research and develops innovative solutions to combat viral infections. His work has garnered attention for its potential to influence therapeutic strategies against viral diseases.

Collaborations

Michael Gale, Jr. has collaborated with notable colleagues, including Michael S. Brown and Jin Ye, contributing to a rich environment of research and innovation.

Conclusion

Michael Gale, Jr. is a key figure in the field of viral research, with a focus on reducing host cell permissiveness to viral replication. His patent and work at The University of Texas System highlight his commitment to advancing scientific knowledge and developing potential treatments for viral infections.